Orange Book product · Brand (NDA)
OMNICEF
CEFDINIR
At a glance
Dec 04, 1997
Approved
Brand (NDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 04, 1997
28 yr 11 mo ago
Today
Pharmaceutical detail
Active ingredient
CEFDINIR
Strength
125MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage form
FOR SUSPENSION
Route
ORAL
TE code
Not listed
Application
NDA 050749
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 1997OMNICEFBrand (NDA)
NDA 050739 · ABBVIE
- 2021CEFDINIRGeneric (ANDA)
ANDA 210220 · ALKEM LABS LTD
- 2021CEFDINIRGeneric (ANDA)
ANDA 210534 · ALKEM LABS LTD
- 2008CEFDINIRGeneric (ANDA)
ANDA 065434 · AUROBINDO PHARMA
- 2007CEFDINIRGeneric (ANDA)
ANDA 065473 · AUROBINDO PHARMA
- 2007CEFDINIRGeneric (ANDA)
ANDA 065418 · ANDA REPOSITORY
- 2007CEFDINIRGeneric (ANDA)
ANDA 065429 · ANDA REPOSITORY
- 2007CEFDINIRGeneric (ANDA)
ANDA 065368 · TEVA PHARMS
- 2007CEFDINIRGeneric (ANDA)
ANDA 065332 · TEVA PHARMS
- 2007CEFDINIRGeneric (ANDA)
ANDA 065330 · CHARTWELL RX
- 2007CEFDINIRGeneric (ANDA)
ANDA 065337 · CHARTWELL RX
- 2006CEFDINIRGeneric (ANDA)
ANDA 065259 · LUPIN
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

